Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.760
+0.230 (5.08%)
At close: Jun 26, 2026, 4:00 PM EDT
4.760
0.00 (-0.01%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Immuneering Employees
Immuneering had 55 employees as of March 31, 2026. The number of employees increased by 2 or 3.77% since the number was last reported on December 31, 2025.
Employees
55
Change
2
Growth
3.77%
Revenue / Employee
n/a
Profits / Employee
-$989,812
Market Cap
307.96M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Bicycle Therapeutics | 288 |
| Lyell Immunopharma | 161 |
| Nautilus Biotechnology | 127 |
| Verastem | 102 |
| SAB Biotherapeutics | 86 |
| Lineage Cell Therapeutics | 77 |
| Cybin | 50 |
IMRX News
- 12 days ago - Immuneering appoints Andrew Gengos as CFO - TheFly
- 12 days ago - Immuneering Appoints Andrew Gengos as Chief Financial Officer - GlobeNewsWire
- 16 days ago - Immuneering Transcript: AGM 2026 - Transcripts
- 16 days ago - Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - GlobeNewsWire
- 26 days ago - Immuneering announces updated clinical data from atebimetinib combination trial - TheFly
- 26 days ago - Immuneering Transcript: Study result - Transcripts
- 26 days ago - Immuneering Press release: Study result - Filings
- 26 days ago - Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO - GlobeNewsWire